RxDoctor Payments DataLook up a doctor →

Ahmed Ali, MD

Internal Medicine · Conway, ARNPI 1841425253

Payments from drug & device makers

$17,568in general payments, 2019–2025

Across 1,102 payments — averaging $15.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$4K
  • AbbVie$4K
  • UCB, Inc.$2K
  • GSK$2K
  • Johnson & Johnson$1K
  • AstraZeneca$659
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$17,560100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,568 in reported general payments places this provider in the 95th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$1,019,576
Medicare patients
295
Services billed
23,354

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide102$139,412
MounjaroTirzepatide92$111,014
EliquisApixaban112$95,766
FarxigaDapagliflozin Propanediol88$79,580
TrulicityDulaglutide51$74,341
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$65,686
JanuviaSitagliptin Phosphate63$61,111
Nurtec OdtRimegepant Sulfate18$42,698
XareltoRivaroxaban44$41,993
JardianceEmpagliflozin34$36,565
Tresiba Flextouch U-100Insulin Degludec32$34,232
EntrestoSacubitril/Valsartan14$26,171
Humalog Kwikpen U-200Insulin Lispro14$23,260
Humulin R U-500 KwikpenInsulin Regular, Human19$22,812
Insulin Lispro Kwikpen U-100Insulin Lispro30$17,758

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$602$185,356143 claims
Novo NordiskOzempic$530$139,412102 claims
PfizerEliquis, Nurtec Odt$404$138,464130 claims
AstraZenecaFarxiga$659$79,58088 claims
MerckJanuvia, Belsomra, Janumet Xr$27$78,22490 claims
GSKTrelegy Ellipta$1,827$65,68665 claims
Johnson & JohnsonXarelto$1,108$41,99344 claims
Boehringer IngelheimJardiance$108$36,56534 claims
NovartisEntresto$396$26,17114 claims
AbbVieLinzess, Synthroid$4,041$15,56834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Conway

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →